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Coenzyme Q10 and non-alcoholic fatty liver disease: an overview 
Abstract 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in the 
UK, for which little effective conventional treatment is available. Mitochondrial 
dysfunction, oxidative stress and inflammation have been implicated in the 
pathogenesis of NAFLD. This article is focussed on the role of the vitamin-like 
substance coenzyme Q10 (CoQ10) in NAFLD, since CoQ10 has a key role in 
mitochondrial function, as well as having antioxidant and anti-inflammatory action. 
CoQ10 levels are depleted in NAFLD, and studies in animal models and human 
subjects have indicated supplementation with CoQ10 can significantly reduce 
oxidative stress and inflammation characteristic of NAFLD. In addition, NAFLD 
patients are at increased risk of developing heart failure, and supplementary CoQ10 
may help to reduce this risk. Supplementary CoQ10 is generally well tolerated, with 
no significant adverse effects reported in long term use. 
Key words 
 coenzyme Q10; non-alcoholic fatty liver disease; mitochondrial dysfunction; oxidative 
stress; inflammation. 
Introduction 
The liver is a complex organ which performs a wide range of essential functions to 
maintain normal health- examples include digestion, immune function and 
detoxification. There are more than one hundred types of liver disease, ranging from 
common disorders such as non-alcoholic fatty liver disease (NAFLD) and alcohol 
related liver disease (ARLD), to less common inherited disorders such as 
haemochromatosis and primary biliary cholangitis. The liver has a high functional 
reserve, and usually liver disorders do not cause any obvious symptoms until the liver 
has suffered a substantial amount of tissue damage; typical symptoms include loss of 
appetite, weight loss and jaundice (Fan, 2010). The liver has a high capacity to 
regenerate damaged tissue, but is eventually compromised by permanent scarring 
(cirrhosis), which represents a common final stage of the different types of liver 
disease (Fan, 2010). Cirrhosis is typically preceded by the deposition of fat within liver 
tissue, which can occur in both alcohol consuming and non-consuming individuals. 
There is currently little effective treatment for NAFLD. This article is focussed on the 
role of CoQ10 deficiency and supplementation in NAFLD. 
Non-alcoholic fatty liver disease 
NAFLD is defined as the accumulation of fat, principally as triglyceride, in hepatic 
cells, exceeding 5-10% of liver weight (Chalasani et al, 2012). NAFLD is the most 
common liver disorder worldwide; its prevalence in the general population is estimated 
at 20-30%, but this rises to 60-70% in obese individuals, and 70-90% in those with 
diabetes (Browning et al, 2004). NAFLD occurs in every age group but especially in 
people in their 40s and 50s. The condition is closely linked to metabolic syndrome, 
which is a cluster of abnormalities including increased abdominal fat, poor ability to 
use the hormone insulin, high blood pressure and high blood levels of triglycerides. 
NAFLD develops in 4 main stages, namely simple steatosis characterised by initial fat 
deposition, non-alcoholic steatohepatitis (NASH) associated with liver inflammation, 
fibrotic scar tissue formation, and cirrhotic liver scarring/liver failure (Benedict & Zhang, 
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2017).Typically 10-20% of patients progress to NASH, with 10-20% of these 
developing fibrosis and ultimately cirrhosis (Pappachan et al, 2017). Liver biopsy 
remains the gold standard for diagnosis of NAFLD.  
Coenzyme Q10 and liver function 
Coenzyme Q10 (CoQ10) is a vitamin-like substance with a number of important 
cellular functions of relevance to liver metabolism and liver disorders. Firstly, CoQ10 
plays a key role in the biochemical process supplying all cells with the energy they 
require for normal functioning; specifically CoQ10 is an intermediate in the electron 
transport system that generates energy in the chemical form of ATP, shuttling 
electrons from complexes I and II to complex III of the mitochondrial respiratory chain 
(Hargreaves, 2003). An adequate supply of CoQ10 is of particular importance in 
tissues with a high energy requirement, such as the liver and heart. Although CoQ10 
is synthesised throughout the body, because of its size and high metabolic capacity, 
the liver is the major site of CoQ10 synthesis. In patients with liver disease where 
metabolic capacity has been compromised, in addition to its direct effect on liver 
function, reduction in CoQ10 production is also likely to have a deleterious effect on 
heart function. 
   Secondly, CoQ10 is a major lipid soluble antioxidant, protecting cell membranes,  
particularly those within mitochondria, from free radical induced oxidative damage 
(Hargreaves, 2003). Such oxidative stress has been implicated in the pathogenesis of 
a number of liver disorders, particularly NAFLD. CoQ10 is the only endogenously 
synthesised liposoluble antioxidant. 
    Thirdly, CoQ10 has been shown to modulate directly the expression of a number of 
genes, including those involved in inflammation and cholesterol synthesis 
respectively. Thus CoQ10 modulates expression of the protein complex nuclear factor 
kappa beta (NFkß), the so-called “master switch” of inflammation (Pala et al, 2016). 
Similarly randomised controlled clinical trials have shown supplemental CoQ10, alone 
or in combination with other supplements, can significantly reduce total blood or LDL 
cholesterol levels. Thus, studies by Schmelzer et al (2011; 150mg CoQ10/day for 2 
weeks) and Monteri et al (2014; 200mg CoQ10 for 12 weeks) reported significant 
reductions of approximately 15% in LDL cholesterol levels following CoQ10 
supplementation. In addition, Mazza et al (2018) showed that treatment with a 
combination of CoQ10 (30mg/day for 2 months) and red yeast rice reduced total and 
LDL cholesterol levels by approximately 20%. 
The three functions of CoQ10 outlined above are of particular relevance to NAFLD; 
increased oxidative stress and inflammation have both been implicated in the 
pathogenesis of NAFLD (Spahis et al, 2017), whilst heart failure has been reported as 
one of the major causes of death in NAFLD patients (Francque et al, 2016). NAFLD is 
associated with heart failure, arrhythmias, valve dysfunction and atherosclerosis 
(Sirbu et al, 2016). Alcohol-related liver disease is similarly associated with an 
increased risk of cardiovascular disorders; these include alcoholic cardiomyopathy, 
arterial hypertension and atrial fibrillation (Milic et al, 2016). 
CoQ10 deficiency 
The body's daily requirement for CoQ10 has not been accurately quantified, but has 
been estimated as 500mg/day; this is based on a total CoQ10 body pool of 2gm and 
average tissue turnover time of 4 days. Most of this daily requirement must be 
manufactured within the body, since a relatively small proportion, estimated at 
5mg/day (Weber et al, 1997), is derived from the normal diet. As people age, the 
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capacity of the body to synthesise its own CoQ10 decreases; optimal production 
occurs around the mid-twenties, with a continual decline in tissue levels thereafter 
(Kalen et al, 1989). In addition to the normal aging process, CoQ10 levels have also 
been shown to be depleted in a variety of disorders, as well as statin type drugs. 
Reduced CoQ10 levels may be a particular problem in patients with fatty liver disease 
prescribed statins, since in addition to inhibiting cholesterol synthesis, statins also 
inhibit the production of CoQ10. Dietary supplementation with CoQ10 therefore 
provides a mechanism to maintain adequate levels within the body, and a rationale for 
the dosages of CoQ10 used in clinical trials, typically 200-400mg/day. 
Preclinical studies on CoQ10 supplementation 
A number of studies in animal models have demonstrated the ability of CoQ10 to 
reduce or prevent the development of liver cirrhosis following a variety of toxic insults; 
these include exposure to medicinal drugs (Fouad & Jresat, 2012), toxic chemicals 
(Choi et al, 2009), and parasitic microorganisms (Othman et al, 2008). For example, 
in the study by Fouad & Jresat (2012), the ability of CoQ10 to protect liver tissue 
against free radical induced oxidative damage was demonstrated; when acute liver 
injury was induced in rats via administration of acetaminophen-more commonly known 
as paracetamol, subsequent administration of CoQ10 reduced cirrhotic tissue damage 
via its antioxidant and anti-inflammatory action. In rats prone to developing NAFLD, 
dietary supplementation with CoQ10 prevented further progression to cirrhosis, via 
down regulation of markers of free radical induced oxidative stress and inflammation 
(Tarry-Adkins et al, 2016). Similarly, in rats fed a high fat diet, supplementation with 
CoQ10 reduced lipid synthesis and increased fatty acid oxidation, resulting in reduced 
serum triglyceride levels, reduced total and LDL cholesterol levels, and reductions in 
weight gain (Chen et al, 2019). 
Clinical studies on CoQ10 supplementation in NAFLD 
With regard to clinical studies, Yessilova et al (2005) found that blood CoQ10 levels 
were depleted in NAFLD patients, with the decrease in CoQ10 correlating with 
increased liver inflammation and cirrhosis. Farhangi et al (2014) reported the first 
randomised controlled trial supplementing CoQ10 in NAFLD patients. The study 
comprised 41 NAFLD patients, 31 male and 10 female aged 20-65 years, diagnosed 
via ultrasonography. Patients supplemented with 100 mg/day CoQ10 for 4 weeks 
showed significant reductions( p<0.05) in the levels of biochemical markers of 
inflammation and oxidative stress (serum aspartate aminotransferase, total 
antioxidant capacity), as well as waist circumference. The most recent randomised 
controlled trial (Farsi et al, 2016) comprised 41 NAFLD patients (28 male, 13 female), 
aged 19-54 years with BMI in the range 25-35 Kg/m2. NAFLD status was established 
by absence of alcohol consumption, elevated liver enzymes, and ultrasonography. The 
grade of hepatic steatosis, defined as the % of hepatocytes containing fat droplets, 
was categorised via a 4 point grading system of normal, mild, moderate and severe. 
Individuals given 100mg CoQ10 per day for 3 months showed significant reductions 
(p<0.05) compared to placebo in the levels of blood markers for liver inflammation and 
damage; aspartate aminotransferase (p=0.012), gamma-glutamyl peptidase, 
(p=0.039), high sensitivity C-reactive protein (p=0.02), TNF-alpha (p=0.049), and a 
lower percentage of liver cells with fat droplet inclusions (reduction in NAFLD grade 
p=0.046). CoQ10 was well tolerated, with no significasnt adverse effects reported, 
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Other clinical studies on CoQ10 of relevance to NAFLD 
As noted above, the risk of developing cardiovascular disease is substantially 
increased in NAFLD patients, with heart failure being a major cause of death. To date 
there have been no randomised controlled trials to investigate the effect of CoQ10 
supplementation specifically on heart failure in NAFLD. However, two randomised 
controlled clinical studies are relevant to this issue, namely Q-SYMBIO and KISEL-10. 
The Q-SYMBIO study was carried out in 420 patients with chronic heart failure, New 
York Heart Association (NYHA) class III and V. The effect of CoQ10 supplementation, 
at a prescribed dose of 3 x 100mg/day for 2 years, on symptoms and biomarker status 
-hence the trial acronym Q-SYMBIO- were assessed, as an adjuvant to conventional 
medication of ACE inhibitors and beta blockers. Assessment included clinical 
examination, echocardiography and pro-BNP status. The primary long-term endpoint 
was time to first major adverse cardiovascular event (MACE), which included 
unplanned hospitalisation due to worsening heart failure and cardiovascular death. 
Supplementation with CoQ10 significantly reduced the relative risk of MACE by 42%, 
with a reduction in both cardiac related deaths (43%) and all cause mortality (42%). 
The authors concluded that these beneficial effects of CoQ10 resulted from improved 
cellular energy provision within heart tissue (Mortensen, 2014). 
The KISEL-10 study was carried out on normal elderly individuals (70-88yrs) from 
the Kinda region of Stockholm (Alehagen et al, 2013); 440 participants were 
supplemented with 200mg/day coenzyme Q10 (CoQ10; Bio-Quinone 100mg) and 
200mcg/day selenium (SelenoPrecise), or placebo, over a 5 year period, hence the 
trial acronym KISEL-10. Clinical examination, echocardiography and biomarker 
measurements were carried out at 6-month intervals. Quality of life was quantified 
using the Short Form-36 (SF-36), Cardiac Health Profile (CHP) and Overall Quality of 
Life (overall-QOL) questionnaires. Supplementation with CoQ10 and selenium 
resulted in a significant reduction in the number of days in hospital, and significantly 
slowed the deterioration in health related quality of life. Echocardiography showed 
significantly better cardiac function in supplemented participants, whose risk of 
cardiovascular mortality was significantly reduced by 53%. Further analysis of data 
from the original study have subsequently been reported; there were significant 
reductions in the blood levels of C-reactive protein and sP-selectin as markers of 
inflammation, and copeptin and adrenomedullin as markers of oxidative stress, in 
addition to levels of pro-BNP. The authors of the KISEL-10 study concluded that the 
reduction in cardiovascular mortality risk in elderly subjects was in part the result of a 
reduction in the fibrosis of cardiac tissue (Alehagen et al, 2018). 
The Q-SYMBIO and KISEL-10 studies thus provide a rationale that 
supplementation with CoQ10 may reduce the risk of heart failure in patients with 
NAFLD, or prevent cardiovascular disease developing in NAFLD patients where this 
is not already present. In addition, these studies provide further evidence for the 
systemic antioxidant, anti-inflammatory and anti-fibrotic activity of CoQ10 of relevance 
to NAFLD. 
Safety of CoQ10 
The safety of CoQ10 has been assessed by Hidaka et al (2008) and Hosoe et al 
(2007). CoQ10 is generally well tolerated, with no serious adverse effects reported in 
long term use. Very rarely, individuals may experience mild gastrointestinal 
disturbance. There are no known toxic effects, and CoQ10 cannot be overdosed. 
CoQ10 is well tolerated in healthy adults at an intake of 900 mg/day, and in rats at a 
dose of up to 1200 mg/Kg/day. In addition, Yamaguchi et al (2009) reported that 
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CoQ10 had no genotoxic activity. CoQ10 is not recommended for pregnant or lactating 
women, in whom the effects of CoQ10 have not been extensively studied. The safety 
of CoQ10 has been confirmed in more than 200 randomised controlled trials, on a 
wide range of disorders. 
Bioavailability of CoQ10 
Bioavailability is defined as the proportion of an ingested substance that reaches 
the blood circulation. Because of its relatively large molecular size and lipid solubility, 
the bioavailability of CoQ10 is intrinsically low. CoQ10 is absorbed from the intestinal 
tract via the same mechanism as other lipid soluble nutrients, via a lipid carrier through 
mucosal cells initially into the lymph, and thence into the bloodstream; thus absorption 
is optimised when CoQ10 is dissolved in a carrier oil, preferably soya or palm oil. The 
delayed peak concentration of CoQ10 in blood is a consequence of this initial 
absorption into the lymphatic system. However, incorporation of supplemental CoQ10 
in liposomal, micellular or nanoparticle form cannot increase the absorption of CoQ10 
through intestinal cells into the lymph. CoQ10 cannot be made more water soluble, as 
any alteration to the molecular structure means that the molecule is no longer CoQ10. 
When supplemental CoQ10 is first produced, via a yeast fermentation process. it is 
obtained in the form of crystals which cannot be absorbed from the digestive tract. It 
is essential that these crystals are dispersed into single CoQ10 molecules, and remain 
dispersed during the product shelf-life, to enable optimum bioavailability; adding 
CoQ10 crystals to a carrier oil without such dispersal, a cost saving technique used by 
some manufacturers, is inadequate. Disparity in the findings of clinical trials 
supplementing CoQ10 in diabetes undoubtedly results from the use of supplements 
with inadequate bioavailability and/or insufficient dosage or treatment duration. These 
issues have been addressed in the recent clinical study of CoQ10 bioavailability by 
Lopez-Lluch et al (2019). The bioavailability of seven different supplement 
formulations containing 100 mg of CoQ10 was evaluated in 14 young healthy 
individuals. Bioavailability was measured as area under the curve of plasma CoQ10 
levels over 48 h after ingestion of a single dose. Measurements were  repeated in the 
same group of 14 volunteers in a double-blind crossover design with a minimum of 4 
wk washout between intakes. Bioavailability of the formulations showed large 
differences that were statistically significant. The best absorbable formulation was a 
soft-gel capsule containing ubiquinone (Bio-Quinone Q10). The matrix used to 
dissolve CoQ10 and the proportion and addition of preservatives such as vitamin C 
affected the bioavailability of CoQ10.  
 
Summary 
 
There is considerable evidence from pre-clinical studies in a number of animal model 
systems for the capacity of supplemental CoQ10 to reduce or prevent liver tissue 
damage by a variety of toxic agents, and these data provide a plausible rationale for 
the supplementation of CoQ10 in patients with liver disease. Although only two 
randomised controlled clinical studies, comprising some 82 patients, supplementing 
CoQ10 in NAFLD  have been carried out to date, the results of significantly reduced 
biomarkers of liver tissue injury have been sufficiently encouraging to consider such a 
novel therapeutic approach in the future management of NAFLD patients. 
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Key points 
1. NAFLD is the most common liver disorder in the UK, for which little effective 
conventional treatment is available. 
2. Mitochondrial dysfunction, oxidative stress and inflammation have been 
implicated in the pathogenesis of NAFLD. 
3. Levels of the vitamin like substance coenzyme Q10 (CoQ10), which has a key 
role in normal mitochondrial function, antioxidant and anti-ctivity, are depleted in 
NAFLD. 
4.Oral supplemention with CoQ10 can significantly reduce oxidative stress and 
inflammation characteristic of NAFLD. 
5. Supplementary CoQ10 is generally well tolerated, with no significant adverse 
effects reported in long term use. 
 
Reflective questions 
1. Reflect on the role of coenzyme Q10 (CoQ10) in normal liver function. 
2. Consider how you would use the information in this article to benefit patients with 
NAFLD. 
3. Reflect on how you would use the information in this article to inform fellow 
healthcare professionals, who may be unfamiliar with the background to NAFLD or 
CoQ10. 
4. Are there other liver disorders which could potentially benefit from 
supplementation with CoQ10? 
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